We are pleased to announce that Marie-Josèphe Champagne has returned to FORUS as Senior Medical Science Liaison (MSL) for Quebec and Atlantic. Marie-Josèphe brings extensive experience from her recent role as National MSL Manager for Hematology, along with more than a...
FORUS Therapeutics Inc. is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Quebec as of November 6th. Further details on the criteria can be found in the links below: Liste des médicaments – Établissement – en vigueur le 6 novembre...
FORUS Therapeutics is thrilled to welcome Lisa Kolomaya as Therapeutic Area Manager, Hematology/Oncology, AB/SK. Lisa is a results-driven life sciences professional with extensive expertise in both oncology and hematology. Guided by a strategic mindset and passion for...
FORUS Therapeutics is thrilled to welcome Erin Webb as Therapeutic Area Manager, Hematology/Oncology, SW ON. Erin began her career as a physician assistant in the US, caring for patients with both benign and malignant hematologic conditions as well as managing...
FORUS Therapeutics is pleased to announce that US-authorized BESREMi® (ropeginterferon alfa-2b-njft), is now available in Canada, via Exceptional Importation. Please note, BESREMi®’s active ingredient, ropeginterferon alfa-2b-njft, has not been reviewed under Health...
FORUS Therapeutics Inc. and PharmaEssentia Corporation have entered into an exclusive licensing agreement for the registration and distribution of BESREMi® (ropeginterferon alfa-2b) for the treatment of polycythemia vera (PV), in Canada. Under the terms of the...
Recent Comments